Benzinga

Benzinga

Benzinga

martes, agosto 25

Inhibrx Biosciences Inc

INBXNASDAQ
Trade with Public
Trade with Public
$104.94
1.311.26%
al cierre: Aug 21, 5:00 PM EST
$104.75
1.121.08%
Premercado: 4:09 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Inhibrx Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Inhibrx Biosciences (INBX).

Price Target Range — 3 Quarters

Analyst Consensus — 4 Analysts

2Buy
2Hold
Consensus RatingBuy# Analysts4Avg. Consensus PT$198Upside to Avg. PT+88.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 24, 2026HC Wainwright & Co.Robert BurnsInitiateBuy$245
Apr 8, 2026StifelDara AzarInitiateBuy$150
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245

HC Wainwright & Co. analyst Robert Burns initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $245.
Benzinga Newsdesk

This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

Top Wall Street analysts changed outlook on top names. See complete rating changes, including upgrades and downgrades, on Benzinga's analyst ratings page.
Avi Kapoor

PRO
Stifel Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $150

Stifel analyst Dara Azar initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $150.
Benzinga Newsdesk

PRO
JMP Securities Reiterates Market Perform on Inhibrx Biosciencesto Market Perform

JMP Securities analyst Reni J. Benjamin reiterates Inhibrx Biosciences (NASDAQ:INBX) from Market Perform to Market Perform.
Benzinga Newsdesk

PRO
JMP Securities Reiterates Market Perform on Inhibrx Biosciencesto Market Perform

JMP Securities analyst Reni Benjamin reiterates Inhibrx Biosciences (NASDAQ:INBX) from Market Perform to Market Perform.
Benzinga Newsdesk

PRO
Citizens Capital Markets Reiterates Market Perform on Inhibrx Biosciencesto Market Perform

Citizens Capital Markets analyst Reni Benjamin reiterates Inhibrx Biosciences (NASDAQ:INBX) from Market Perform to Market Perform.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved